New funds to boost European life sciences European investment firm LSP has closed its European life sciences fund LSP at €1 bn. Additionally, a €10bn fund of funds was greenlighted at the EU Council in Paris. more ➔
Aicuris licences antisense RNA know-how from Hybridize TherapeuticsAiCuris will pay up to €100m to Dutch Hybridize Therapeutics BV for the development of antisense RNA therapeutics that stop BK viraemia in renal transplant patients. more ➔
BioNTech collaborates with AGC BiologicsAGC Biologics supports BioNTech’s manufacturing of an Omicron-based vaccine with plasmids for in vitro transcription. more ➔
EU Council confirms European Scale-up InitiativeEU Members States agreed on Tuesday to launch the pan-European Scale-up Initiative, which is aimed to provide €10bn for late-state tech companies. more ➔
Protix raises €50m for expansionDutch insect protein specialist Protix has raised €50m for expansion and development from international investors and the ECBF. more ➔
Viennese Ribbon Biolabs closes €18m Series A financingRibbon Biolabs has cashed in €18m in Series A financing led by Hadean Ventures more ➔
mRNA specalist Ethris raises $26m in Series B financingGerman mRNA and LNP specialist Ethris GmbH has closed a $26m Series B round led by Laureus Capital. more ➔
Evotec and Boehringer Ingelheim enter drug discovery deal Evotec SE will use its PanOmics platform to validate and screen targets and drug candidates in ophtalmology for Boehringer Ingelheim. more ➔
BioNTech and Pfizer evaluate Omicron-specific vaccinePfizer Inc and BioNTech SE have started clinical safety testing of an Omikron-specific vaccine in healthy adults 18 through 55 years of age. more ➔
Cytovation AS kicks-off with $20m Series A financingNorway’s immuno-oncology specialist Cytovation A/S has raised $20m in a Series A financing led by early-stage investor Sandwater. more ➔
